---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-074529"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:30:07.961486+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx shareholders approve amended incentive plan, elect directors, ratify auditor

## Summary
- Stockholders approved Second Amended and Restated 2023 Incentive Plan, authorizing up to 11.5M new shares plus forfeited shares from prior plans.
- Class III directors Matthew K. Fust and Amrit Ray, M.D. elected to Board for term expiring 2028.
- Advisory vote on executive compensation received 55.1M for (68%) vs 26.1M against.
- Ernst & Young ratified as fiscal 2025 independent auditor with 84.3M votes for.
- Broker non-votes of 5.3M shares on director election, incentive plan, and say-on-pay proposals.

## SEC filing metadata
- accession: 0000950170-25-074529
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017025074529/0000950170-25-074529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017025074529/rare-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-074529
- JSON: https://secwatch.observer/filing/0000950170-25-074529.json
- Plain text: https://secwatch.observer/filing/0000950170-25-074529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.